TP53 and acute myeloid leukemia: Nevertheless, xenograft-bearing mice with TP53-mutant AML cells under combination treatment survived almost twice as long than those treated with either agent alone using the same dose and treatment schedule as we previously described, in which a VEN/HMA resistant TP53-WT PDX model showed a three-fold survival extension [28].